Royalty Pharma (RPRX) Capital Expenditures Growth (1y) (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Capital Expenditures Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Orix | 44.91 Bn | 45.24 Bn | 4.68 Bn | - |
| 2 | Royalty Pharma | 36.78 Bn | 38.89 Bn | - | 22,433.30% |
| 3 | Royal Gold | 22.19 Bn | 22.06 Bn | 390.45 Mn | - |
| 4 | OR Royalties | 6.98 Bn | 6.91 Bn | 82.22 Mn | - |
| 5 | Encore Capital | 2.06 Bn | 1.88 Bn | 455.04 Mn | - |
| 6 | Atlanticus Holdings | 1.41 Bn | 853.17 Mn | 686.46 Mn | - |
| 7 | Jefferson Capital | 1.23 Bn | 1.21 Bn | - | - |
| 8 | Upbound | 1.11 Bn | 1.00 Bn | 594.84 Mn | -15.07% |
| 9 | Lufax Holding | 1.08 Bn | -1.19 Bn | - | - |
| 10 | Metalla Royalty & Streaming | 957.79 Mn | 946.72 Mn | 4.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22,433.30% |
| Mar 31, 2026 | 42,697.16% |
| Dec 31, 2025 | 47.80% |
| Sep 30, 2025 | -19.48% |
| Jun 30, 2025 | -99.85% |
| Mar 31, 2025 | -98.77% |
| Dec 31, 2024 | -50.47% |
| Sep 30, 2024 | 164.79% |
| Jun 30, 2024 | 1,105.42% |
| Mar 31, 2024 | -85.69% |
| Dec 31, 2023 | 300.51% |
| Sep 30, 2023 | -65.73% |
| Jun 30, 2023 | -65.46% |
| Mar 31, 2023 | 707,788.24% |
| Dec 31, 2022 | 45.71% |
| Sep 30, 2022 | -1.48% |
| Jun 30, 2022 | -3.13% |
| Mar 31, 2022 | -99.98% |
| Dec 31, 2021 | -78.67% |
| Sep 30, 2021 | 66.49% |